Research ExplorerPublicationsLong-term outcome of liver transplant patients with Budd-Chi...

Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms

Standard

Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. / Potthoff, Andrej; Attia, Dina; Pischke, Sven; Mederacke, Ingmar; Beutel, Gernot; Rifai, Kinan; Deterding, Katja; Heiringhoff, Karlheinz; Klempnauer, Jürgen; Strassburg, Christian P; Manns, Michael P; Bahr, Matthias J.

In: LIVER INT, 08.2015.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Potthoff, A, Attia, D, Pischke, S, Mederacke, I, Beutel, G, Rifai, K, Deterding, K, Heiringhoff, K, Klempnauer, J, Strassburg, CP, Manns, MP & Bahr, MJ 2015, 'Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms', LIVER INT. https://doi.org/10.1111/liv.12816

APA

Potthoff, A., Attia, D., Pischke, S., Mederacke, I., Beutel, G., Rifai, K., Deterding, K., Heiringhoff, K., Klempnauer, J., Strassburg, C. P., Manns, M. P., & Bahr, M. J. (2015). Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. LIVER INT. https://doi.org/10.1111/liv.12816

Vancouver

Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. LIVER INT. 2015 Aug. https://doi.org/10.1111/liv.12816

Bibtex

@article{92017d1525824b359f538d730a27fcee,
title = "Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms",
abstract = "BACKGROUND: A considerable proportion of patients receiving liver transplants for Budd-Chiari syndrome (BCS) suffer from myeloproliferative neoplasms (MPN). This study evaluated the long-term prognosis of liver-transplanted patients with BCS secondary to MPN and the effect of immunosuppression on MPN progression.METHODS: A total of 78 patients with BCS were evaluated between 1982 and 2013. Of those, 40 patients suffered from polycythaemia vera (PV) and essential thrombocythaemia (ET). One patient had primary myelofibrosis (PMF). All patients received the standard immunosuppressive regimen. We retrospectively evaluated the long-term survival, clinical course and laboratory parameters of patients with MPN.RESULTS: Exactly 29/41 patients (71%) with MPN survived ≥ 3 years [mean age 36 ± 11 years; females n = 27 (93%)]. Mean follow-up after orthotopic liver transplantation (OLT) was 12.4 ± 7.3 years (range 3-28 years). Five- and 10-year survival rates were not significantly different in patients with and without MPN (P = 0.81 and P = 0.66 respectively) or in patients with PV and ET (P = 0.29 and P = 0.55 respectively). Thrombosis and bleeding developed in 7/29 (24%) long-term MPN survivors with no significant difference between ET and PV (P = 0.18). In the long-term follow-up, there was no evidence of progression to overt myelofibrosis or acute myeloid leukaemia (AML). In the uni- and multivariate Cox-regression analyses, MPN did not influence survival after OLT.CONCLUSIONS: Budd-Chiari syndrome patients with and without underlying MPN had similar long-term survival rates after OLT. There was no evidence of enhanced progression of MPN after OLT secondary to immunosuppressive therapy. However, major haemorrhage and recurrent thrombosis contributed to morbidity and mortality after OLT in those patients.",
author = "Andrej Potthoff and Dina Attia and Sven Pischke and Ingmar Mederacke and Gernot Beutel and Kinan Rifai and Katja Deterding and Karlheinz Heiringhoff and J{\"u}rgen Klempnauer and Strassburg, {Christian P} and Manns, {Michael P} and Bahr, {Matthias J}",
note = "{\textcopyright} 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2015",
month = aug,
doi = "10.1111/liv.12816",
language = "English",
journal = "LIVER INT",
issn = "1478-3223",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms

AU - Potthoff, Andrej

AU - Attia, Dina

AU - Pischke, Sven

AU - Mederacke, Ingmar

AU - Beutel, Gernot

AU - Rifai, Kinan

AU - Deterding, Katja

AU - Heiringhoff, Karlheinz

AU - Klempnauer, Jürgen

AU - Strassburg, Christian P

AU - Manns, Michael P

AU - Bahr, Matthias J

N1 - © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2015/8

Y1 - 2015/8

N2 - BACKGROUND: A considerable proportion of patients receiving liver transplants for Budd-Chiari syndrome (BCS) suffer from myeloproliferative neoplasms (MPN). This study evaluated the long-term prognosis of liver-transplanted patients with BCS secondary to MPN and the effect of immunosuppression on MPN progression.METHODS: A total of 78 patients with BCS were evaluated between 1982 and 2013. Of those, 40 patients suffered from polycythaemia vera (PV) and essential thrombocythaemia (ET). One patient had primary myelofibrosis (PMF). All patients received the standard immunosuppressive regimen. We retrospectively evaluated the long-term survival, clinical course and laboratory parameters of patients with MPN.RESULTS: Exactly 29/41 patients (71%) with MPN survived ≥ 3 years [mean age 36 ± 11 years; females n = 27 (93%)]. Mean follow-up after orthotopic liver transplantation (OLT) was 12.4 ± 7.3 years (range 3-28 years). Five- and 10-year survival rates were not significantly different in patients with and without MPN (P = 0.81 and P = 0.66 respectively) or in patients with PV and ET (P = 0.29 and P = 0.55 respectively). Thrombosis and bleeding developed in 7/29 (24%) long-term MPN survivors with no significant difference between ET and PV (P = 0.18). In the long-term follow-up, there was no evidence of progression to overt myelofibrosis or acute myeloid leukaemia (AML). In the uni- and multivariate Cox-regression analyses, MPN did not influence survival after OLT.CONCLUSIONS: Budd-Chiari syndrome patients with and without underlying MPN had similar long-term survival rates after OLT. There was no evidence of enhanced progression of MPN after OLT secondary to immunosuppressive therapy. However, major haemorrhage and recurrent thrombosis contributed to morbidity and mortality after OLT in those patients.

AB - BACKGROUND: A considerable proportion of patients receiving liver transplants for Budd-Chiari syndrome (BCS) suffer from myeloproliferative neoplasms (MPN). This study evaluated the long-term prognosis of liver-transplanted patients with BCS secondary to MPN and the effect of immunosuppression on MPN progression.METHODS: A total of 78 patients with BCS were evaluated between 1982 and 2013. Of those, 40 patients suffered from polycythaemia vera (PV) and essential thrombocythaemia (ET). One patient had primary myelofibrosis (PMF). All patients received the standard immunosuppressive regimen. We retrospectively evaluated the long-term survival, clinical course and laboratory parameters of patients with MPN.RESULTS: Exactly 29/41 patients (71%) with MPN survived ≥ 3 years [mean age 36 ± 11 years; females n = 27 (93%)]. Mean follow-up after orthotopic liver transplantation (OLT) was 12.4 ± 7.3 years (range 3-28 years). Five- and 10-year survival rates were not significantly different in patients with and without MPN (P = 0.81 and P = 0.66 respectively) or in patients with PV and ET (P = 0.29 and P = 0.55 respectively). Thrombosis and bleeding developed in 7/29 (24%) long-term MPN survivors with no significant difference between ET and PV (P = 0.18). In the long-term follow-up, there was no evidence of progression to overt myelofibrosis or acute myeloid leukaemia (AML). In the uni- and multivariate Cox-regression analyses, MPN did not influence survival after OLT.CONCLUSIONS: Budd-Chiari syndrome patients with and without underlying MPN had similar long-term survival rates after OLT. There was no evidence of enhanced progression of MPN after OLT secondary to immunosuppressive therapy. However, major haemorrhage and recurrent thrombosis contributed to morbidity and mortality after OLT in those patients.

U2 - 10.1111/liv.12816

DO - 10.1111/liv.12816

M3 - SCORING: Journal article

C2 - 25736096

JO - LIVER INT

JF - LIVER INT

SN - 1478-3223

ER -